Daraxonrasib doubles survival in metastatic pancreatic cancer in Phase 3 RASolute 302
Patients with metastatic pancreatic cancer who relapsed after first-line chemo now have an oral drug that doubled survival in a Phase 3 trial. Daraxonrasib from Revolution Medicines $RVMD raised median overall survival to 13.2 months vs 6.7 on chemo, a 60% cut in death risk. Now
For patients whose metastatic pancreatic cancer has already progressed after one round of chemotherapy, the options have been bleak and survival is usually counted in a handful of months. New Phase 3 results change that picture. In the RASolute 302 trial, a once-daily oral drug called daraxonrasib, developed by Revolution Medicines $RVMD, raised median overall survival to 13.2 months compared with 6.7 months for standard intravenous chemotherapy. That works out to a 60% reduction in the risk of death (hazard ratio 0.40). The trial enrolled 500 patients across 59 sites in six countries, and the findings were published in the New England Journal of Medicine and presented at the ASCO annual meeting. Daraxonrasib belongs to a class known as pan-RAS inhibitors, which target a family of mutations that drive most pancreatic tumors and have long been considered hard to attack with drugs. The US Food and Drug Administration has granted it Breakthrough Therapy Designation, a status meant to speed review. Two further Phase 3 studies are testing the drug in earlier-stage disease.